Loss of cardio-protective effects at the ADAMTS7 locus due to gene-smoking interactions by Saleheen, Danish et al.
 
 
 
 
Saleheen, D. et al. (2017) Loss of cardio-protective effects at the 
ADAMTS7 locus due to gene-smoking interactions. Circulation, 135(24), 
pp. 2336-2353. (doi:10.1161/CIRCULATIONAHA.116.022069) 
 
This is the author’s final accepted version. 
 
There may be differences between this version and the published version. 
You are advised to consult the publisher’s version if you wish to cite from 
it. 
 
 
 
 
http://eprints.gla.ac.uk/141064/ 
     
 
 
 
 
 
 
Deposited on: 23 May 2017 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
1 
 
Loss of cardio-protective effects at the ADAMTS7 locus due to gene-smoking interactions  1 
Danish Saleheen PhD,1,2 Wei Zhao MSc,1 Robin Young PhD,3 Christopher P Nelson PhD,4 2 
WeangKee Ho PhD,3 Jane Ferguson PhD,5 Asif Rasheed MBBS,2 Kristy Ou BS,5 Sylvia T Nurnberg 3 
PhD,57 Robert C. Bauer PhD,76 Anuj Goel MSc,6 Ron Do PhD,7,8 Alexandre FR Stewart PhD,9 Jaana 4 
Hartiala PhD,10 Weihua Zhang PhD,11,12 Gudmar Thorleifsson PhD,50,51 Rona J Strawbridge PhD,13 5 
Juha Sinisalo PhD,61 Stavroula Kanoni PhD,15 Sanaz Sedaghat PhD,16 Eirini Marouli PhD,15,17 Kati 6 
Kristiansson PhD,18 Jing Hua PhD,19 Robert Scott PhD,19 Dominique Gauguier PhD,20 Svati Shah 7 
MD,21 Albert Vernon Smith PhD,22,36 Natalie R van Zuydam PhD,23 Amanda J Cox PhD,24 Christina 8 
Willenborg PhD,25,26, Thorsten Kessler MD,27,28 Lingyao Zeng PhD,27,29 Michael A Province PhD,30 9 
Andrea Ganna PhD,31,32 Lars Lind PhD,33 Nancy L. Pedersen PhD,34 Charles C White PhD,35 Anni 10 
Joensuu MSc,18,37 Marcus E Kleber PhD,38 Alistair S Hall PhD,39 Winfried März PhD,40 Veikko 11 
Salomaa PhD,18  Christopher O'Donnell MD,41 Erik Ingelsson PhD,42,43 Mary F Feitosa PhD,30 12 
Jeanette Erdmann PhD,25,26 Donald W. Bowden PhD,24 Colin N Palmer PhD,23 Vilmundur Gudnason 13 
PhD,22,36 Ulf De Faire PhD,44 Pierre Zalloua PhD,45 Nick Wareham PhD,20 John R Thompson PhD,46 14 
Kari Kuulasmaa PhD,18 George Dedoussis PhD,17 Markus Perola PhD,18,37 Abbas Dehghan PhD,16 15 
John C Chambers PhD,11,12,47 Jaspal Kooner MD,11,47,48 Hooman Allayee PhD,10 Panos Deloukas 16 
PhD,15,49 Ruth McPherson PhD,9 Kari Stefansson PhD,50,51 Heribert Schunkert MD,27,29 Sekar 17 
Kathiresan MD,52-55 Martin Farrall PhD,6 EPIC-CVD,3 Philippe Frossard DSC,2 Daniel J Rader 18 
MD,56,57 Nilesh Samani MD,4 PROMIS,2 CARDIoGRAMplusC4D, Muredach P. Reilly MD.76 19 
Collaborators: 20 
Stanley L. Hazen MD,58 W.H. Wilson Tang MD,58 Perttu P Salo PhD,18,37 Marja-Liisa Lokki PhD,60 21 
Markku S Nieminen PhD,61 Antti-Pekka Sarin MSc,18,37 Alun Evans MSc,63 Jean Ferrières MD,64 22 
Jarmo Virtamo PhD,18 Frank Kee PhD,66 David-Alexandre Trégouët PhD,67 Dominique Arveiler 23 
PhD,68 Philippe Amouyel PhD,69 Paolo Brambilla PhD,70 Annette Peters PhD,71 Melanie 24 
Waldenberger PhD,71,75 Giovanni Veronesi PhD,72 Giancarlo Cesana PhD,73 Satu Männistö PhD,18 25 
Pekka Jousilahti PhD,18 Antti M Jula PhD,18 Kennet Harald PhD,18 Albert Hofman PhD,16 Oscar H. 26 
Franco PhD,16 Andre G. Uitterlinden PhD.74 27 
 28 
1. Department of Biostatistics and Epidemiology, University of Pennsylvania, USA 29 
2. Center for Non-Communicable Diseases, Karachi, Pakistan. 30 
3. Department of Public Health and Primary Care, University of Cambridge, UK 31 
4. Department of Cardiovascular Sciences, University of Leicester, Leicester, LE3 9QP, UK 32 
5. Cardiology Division, Department of Medicine, Vanderbilt University, Nashville, USA  33 
6. Division of Cardiovascular Medicine, Radcliffe Department of Medicine & Wellcome Trust Centre for Human 34 
Genetics, University of Oxford, UK 35 
 36 
7. The Charles Bronfman Institute of Personalized Medicine, Icahn School of Medicine at Mount Sinai, New 37 
York, NY, USA 38 
 39 
8. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 40 
USA 41 
 42 
9. Ruddy Canadian Cardiovascular Genetics Centre, University of Ottawa Heart Institute, Ottawa, Canada 43 
 44 
10. Institute for Genetic Medicine and Department of Preventive Medicine, Keck School of Medicine, University 45 
of Southern California, Los Angeles, CA 90033 46 
2 
 
11. Department of Epidemiology and Biostatistics, Imperial College London, London, UK 47 
12. Department of Cardiology, Ealing Hospital NHS Trust, Middlesex, UK 48 
13. Cardiovascular Medicine Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden 49 
14. Department of Medicine, Department of Cardiology, Helsinki University Central Hospital, Helsinki, Finland 50 
15. William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary 51 
University of London, London, UK 52 
16. Department of Epidemiology, Erasmus University Medical center, Rotterdam, The Netherlands 53 
17. Department of Dietetics-Nutrition, Harokopio University, 70 El. VenizelouStr, Athens, Greece  54 
18. National Institute for Health and Welfare, Helsinki, Finland 55 
19. MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge School of Clinical 56 
Medicine, Box 285, Cambridge Biomedical Campus, Cambridge, CB2 0QQ 57 
20. INSERM, UMRS1138, Centre de Recherche des Cordeliers, Paris, France 58 
21. Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC 27710 59 
22. Icelandic Heart Association, Kopavogur, Iceland   60 
23. Medical Research Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK 61 
24. Center for Genomics and Personalized Medicine Research, Wake Forest School of Medicine, Winston-62 
Salem, NC, USA 63 
25. Institut für Integrative und Experimentelle Genomik, Universität zu Lübeck, Lübeck, Germany 64 
26. DZHK (German Research Center for Cardiovascular Research) partner site Hamburg–Lübeck–Kiel, 65 
Lübeck, Germany 66 
27. Deutsches Herzzentrum München, Technische Universität München, München, Germany 67 
28. Klinikum rechts der Isar, München, Germany 68 
29. DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, München, 69 
Germany 70 
30. Department of Genetics, Washington University School of Medicine, St. Louis, MO 71 
31. Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital and 72 
Harvard Medical School, Boston, Massachusetts 02114, USA 73 
32. Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, 7 Cambridge Center, 74 
Cambridge, Massachusetts 02142, USA 75 
33. Department of Medical Sciences, Cardiovascular Epidemiology, Uppsala University, Uppsala, Sweden 76 
34. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden 77 
35. Department of Biostatistics Boston University School of Public Health Framingham Heart Study 801 78 
Massachusetts Avenue, CT3 Boston, MA 02118 79 
36. Faculty of Medicine, University of Iceland, Reykjavik, Iceland 80 
37. University of Helsinki, Institute for Molecular Medicine, Finland (FIMM) 81 
38. Department of Medicine, Mannheim Medical Faculty, Heidelberg University 82 
39. Leeds Institute of Genetics, Health and Therapeutics, University of Leeds, UK 83 
40. Synlab Academy, Synlab Services GmbH, Mannheim, Germany and Clinical Institute of Medical and 84 
Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria 85 
41. National Heart, Lung, and Blood Institute and the Framingham Heart Study, National Institutes of Health, 86 
Bethesda, MD 87 
42. Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala 88 
University, Uppsala, Sweden 89 
43. Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, 90 
Stanford, California, USA 91 
44. Division of Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, 92 
Stockholm, Sweden 93 
45. Lebanese American University, School of Medicine, Beirut 1102 2801, Lebanon 94 
46. Department of Health Sciences, University of Leicester, Leicester, UK 95 
47. Imperial College Healthcare NHS Trust, London, UK 96 
48. Cardiovascular Science, National Heart and Lung Institute, Imperial College London, London, UK 97 
49. Princess Al-Jawhara Al-Brahim Centre of Excellence in Research of Hereditary Disorders (PACER-HD), 98 
King Abdulaziz University, Jeddah, Saudi Arabia 99 
50. deCODE Genetics, Sturlugata 8, IS-101 Reykjavik, Iceland 100 
51. University of Iceland, School of Medicine, 101 Reykjavik, Iceland 101 
3 
 
52. Broad Institute of the Massachusetts Institute of Technology and Harvard University, Cambridge, 102 
Massachusetts, USA 103 
53. Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA 104 
54 Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts, USA 105 
55. Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA 106 
56. Department of Genetics, University of Pennsylvania, USA 107 
57. Division of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of 108 
Medicine, University of Pennsylvania, USA 109 
58. Departments of Cardiovascular Medicine and Cellular and Molecular Medicine, Cleveland Clinic, 110 
Cleveland, OH 44195  111 
60. Transplantation Laboratory, Haartman Institute, Helsinki, Finland 112 
61. Heart and Lung Center HUH, Helsinki University Hospital and Helsinki University, Finland 113 
63. Centre for Public Health, The Queen's University of Belfast, Belfast, Northern Ireland 114 
64. INSERM UMR 1027, Department of Cardiology, Toulouse University School of Medicine, Rangueil 115 
Hospital, 31059 Toulouse, France 116 
66. UKCRC Centre of Excellence for Public Health (NI), Queens University of Belfast, Northern Ireland 117 
67. Institut National pour la Santé et la Recherche Médicale (INSERM), Unité Mixte de Recherche en Santé 118 
(UMR_S) 1166, F-75013, Paris, France AND Sorbonne Universités, Université Pierre et Marie Curie, Paris, 119 
France; and Institute for Cardiometabolism and Nutrition, Paris, France 120 
68. Department of Epidemiology and Public Health, EA3430, University of Strasbourg, Faculty of Medicine, 121 
Strasbourg, France 122 
69. Institut Pasteur de Lille, INSERM U744, Université Lille Nord de France, F-59000 Lille, France 123 
70. Laboratory Medicine, Hospital of Desio, Department of Health Sciences, University of Milano, Bicocca, Italy 124 
71. Institute of Epidemiology II, Helmholtz Zentrum München, Neuherberg, Germany AND German Center for 125 
Cardiovascular Disease Research (DZHK e.V.), Munich, Germany Melanie Waldenberger 126 
72. EPIMED Research Center, Department of Clinical and Sperimental Medicine, University of Insubria, 127 
Varese, Italy 128 
73. University of Milano, Bicocca, Italy 129 
74. Department of Internal Medicine, Erasmus University Medical center, Rotterdam, The Netherlands 130 
75. Research Unit of Molecular Epidemiology, Helmholtz Zentrum München, Neuherberg, Germany 131 
76. Cardiology Division, Department of Medicine and the Irving Institute for Clinical and Translational 132 
Research, Columbia University Medical Center, New York, USA 133 
 134 
Corresponding authors: 135 
Danish Saleheen, MBBS, PhD  136 
Assistant Professor of Biostatistics and Epidemiology 137 
University of Pennsylvania 138 
11-134 Translational Research Center 139 
3400 Civic Center Boulevard  140 
Philadelphia, PA 19104 141 
Tel: 215-573-6323 142 
Fax: 215-573-2094 143 
Email: saleheen@mail.med.upenn.edu 144 
 145 
Muredach P. Reilly, MBBCH, MSCE 146 
Herbert and Florence Irving Professor of Medicine 147 
Director of the Irving Institute for Clinical and Translational Research 148 
Columbia University 149 
622 West 168th Street, PH10-305 150 
New York, NY 10032 151 
Tel: 212-305-9453 152 
Fax: 212-305-3213 153 
Email: mpr2144@cumc.columbia.edu 154 
4 
 
ABSTRACT 155 
Background Common diseases such as coronary heart disease (CHD) are complex in etiology. The 156 
interaction of genetic susceptibility with lifestyle factors may play a prominent role. However, gene-157 
environment interactions for CHD have been difficult to identify. Here, we investigate interaction of 158 
smoking behavior, a potent lifestyle factor, with genotypes that have been shown to associate with 159 
CHD risk.  160 
Methods We analyzed data on 60,919 CHD cases and 80,243 controls from 29 studies for gene-161 
smoking interactions for genetic variants at 45 loci previously reported to associate with CHD risk. 162 
We also studied 5 loci associated with smoking behavior. Study specific gene-smoking interaction 163 
effects were calculated and pooled using fixed-effects meta-analyses. Interaction analyses were 164 
declared to be significant at a P-value < 1.0x10-3 (Bonferroni correction for 50 tests).  165 
Results We identified novel gene-smoking interaction for a variant upstream of the ADAMTS7 gene. 166 
Every T allele of rs7178051 was associated with lower CHD risk by 12% in never-smokers (P-value: 167 
1.3x10-16) compared to 5% in ever-smokers (P-value: 2.5x10-4) translating to a 60% loss of CHD 168 
protection conferred by this allelic variation in people who smoked tobacco (Interaction P-value: 169 
8.7x10-5). The protective T allele at rs7178051 was also associated with reduced ADAMTS7 170 
expression in human aortic endothelial cells and lymphoblastoid cell lines. Exposure of human 171 
coronary artery smooth muscle cells to cigarette smoke extract led to induction of ADAMTS7. 172 
Conclusion Allelic variation at rs7178051 that associates with reduced ADAMTS7 expression 173 
confers stronger CHD protection in “never-smokers” compared to “ever-smokers”. Increased 174 
vascular ADAMTS7 expression may contribute to the loss of CHD protection in smokers.    175 
Key words: Gene-smoking interaction, gene-environment interaction, coronary heart disease, 176 
ADAMTS7, smoking. 177 
Word count: 269 178 
 179 
  180 
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Clinical Perspective 181 
1) What is new?  182 
 183 
• Using data on 60,919 CHD cases and 80,243 controls, this study conducted gene-184 
environment interaction analyses to investigate effect modification by smoking behavior at 185 
established CHD and smoking related loci. 186 
• Cardio-protective effects conferred by allelic variation at the ADAMTS7 locus attenuated by 187 
60% in people who smoked tobacco compared to those who did not smoke. 188 
• Allelic variation at ADAMTS7 associated with reduced CHD risk was associated with reduced 189 
ADAMTS7 expression in human aortic endothelial cells and lymphoblastoid cell lines. 190 
• Exposure of human coronary artery smooth muscle cells to cigarette smoke extract led to 191 
induction of ADAMTS7. 192 
 193 
2) What are the clinical implications?  194 
 195 
• These human genomic data provide new insights into potential mechanisms of CHD in 196 
cigarette smokers.  197 
• Findings from this study also point towards the directional impact of the ADAMTS7 locus on 198 
CHD. 199 
• ADAMTS7 and its substrates have a specific role in cigarette smoking related CHD. 200 
• Inhibition of ADAMTS7 is a novel potential therapeutic strategy for CHD that may have 201 
particular benefits in individuals who smoke cigarettes. 202 
 203 
 204 
 205 
 206 
 207 
 208 
 209 
 210 
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INTRODUCTION 211 
Coronary heart disease (CHD) is a complex disorder resulting from the interplay of lifestyle 212 
and genetic factors.1, 2 Yet, gene-environment interactions for CHD have been difficult to identify. 213 
Cigarette smoking is one of the strongest lifestyle risk factors for CHD but the underlying molecular 214 
mechanisms of CHD in humans who smoke remain uncertain.3-5  Cigarette smoking accounts for 215 
one-fifth of all CHD events globally and is responsible for ~1.6 million deaths attributable to CHD 216 
annually.6 Genome-wide association studies (GWAS) have improved our understanding on the 217 
genetic predisposition to both CHD and smoking behavior.7-10 Joint or interactive effects of genetic 218 
variation and smoking behavior in the etiology of CHD, however, remain poorly understood. GWAS 219 
can provide new opportunities to investigate gene-smoking interactions.  220 
We hypothesized that genetic predisposition to CHD is modified by cigarette smoking at 221 
loci discovered by GWAS to be associated with either CHD or smoking behavior. We conducted a 222 
focused experiment at 50 main-effect loci (45 for CHD and 5 for smoking behavior) using genetic 223 
data and information on smoking behavior in 60,919 CHD cases and 80,243 controls from 29 224 
different studies. We report novel findings on gene-smoking interactions in CHD. Allelic variation on 225 
chr.15q25.1 at ADAMTS7 is associated with protection from CHD in “never-smokers” with 226 
attenuation of this protective effect in people who smoked. Expression studies in relevant vascular 227 
cells support a role for ADAMTS7 in smoking induced CHD.  These data provide the first insights on 228 
the etiology of CHD in cigarette smokers and may present opportunities for targeted therapeutic 229 
strategies to lower CHD risk in individuals who smoke cigarettes. 230 
 231 
 232 
 233 
 234 
 235 
 236 
 237 
 238 
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METHODS 239 
Summary of study Design  240 
All studies participating in the CARDIoGRAMplusC4D consortium7-9 that had information 241 
available on smoking status, CHD risk and genotypes at the 50 CHD and smoking behavior-242 
associated loci were invited to participate. The current study had five inter-related components 243 
(eFigure-1). First, as part of the quality control, we investigated the association of smoking status 244 
with CHD risk within each study. Second, we performed an updated analysis of all the SNPs (± 50 245 
KB) at the 45 established CHD loci to identify the variant with the strongest CHD association in our 246 
study population at each established CHD locus. Effect estimates from each study in association 247 
with CHD risk were obtained and pooled to identify the strongest CHD associated variant (“lead 248 
variant”). Third, we investigated gene-smoking interactions at these 45 CHD loci and at 5 loci related 249 
to smoking behavior. Fourth, for loci demonstrating differential CHD associations by smoking status, 250 
we mapped the interaction region, examined linkage disequilibrium (LD) across the region and 251 
performed conditional analyses to identify independent genetic signals. Finally, for loci exhibiting 252 
gene-smoking interaction in CHD, we assessed eQTL data for association of variants with 253 
expression of local genes in available datasets and examined expression of these genes in multiple 254 
cell types that play prominent roles in smoking-CHD pathobiology.  255 
Harmonization of phenotypes and genotypes 256 
Summary level estimates for each study were shared via a secure FTP site. We used 257 
“ever-smoking” as a primary exposure and data were harmonized by uniformly characterizing 258 
participants in each study into two categories, “ever-smokers” and “never-smokers”. “Ever-smokers” 259 
were defined as those who had smoked more than 100 cigarettes in a lifetime. For case-control 260 
studies, information on “ever smoking” status collected at the time of enrollment was used for the 261 
current analyses; whereas for prospective cohort studies, information on smoking status obtained at 262 
the baseline visit was used for the current investigation. CHD was defined based on evidence from 263 
angiography or history of verified myocardial infarction (MI), percutaneous coronary interventions 264 
(PCI) or coronary artery bypass grafting (CABG) as published in CARDIoGRAMplusC4D projects.7-9  265 
Genotype data generated through GWAS (directly genotyped or imputed) or cardio-metabochip 266 
(directly genotyped only) arrays were obtained from each study and all genetic data were aligned 267 
using the build-37 reference panel. Imputed SNPs were removed if they had any of the following: (i) 268 
a minor allele frequency of <1%; (ii) info score of <0.90; or (iii) confidence score <0.90. For each 269 
study, GWAS data were imputed using the Phase II CEU HapMap reference population.11 Standard 270 
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quality control criteria were applied by each participating study, as described previously.7 All 271 
participating studies in the CARDIoGRAMplusC4D consortium were approved by their locally 272 
relevant institutional review boards and all participants gave written informed consent before their 273 
enrollment in each study. 7-9 274 
STATISTICAL ANALYSIS 275 
Gene-smoking interaction analyses 276 
Initial quality control and association of established CHD loci with CHD risk: As part of an initial 277 
quality control, effect estimates from each study were obtained for “ever-smoking” status and CHD 278 
risk using a case-control logistic regression model adjusted for age and sex. Each participating study 279 
also assessed and, if needed, controlled for population stratification by including principal 280 
components as covariates in the regression model as described earlier.7-9 To identify variant(s) with 281 
the most significant association with CHD risk at established CHD loci in our study population, 282 
logistic regression analyses were conducted by each participating study for all the SNPs flanking 283 
(±50 kb) the lead variant previously reported at each CHD locus.  Effect estimates and standard 284 
errors were obtained and meta-analyzed using a fixed-effects inverse variance approach. All lead 285 
variants identified through these analyses were further investigated for gene-smoking interactions in 286 
CHD. One lead variant per locus was selected for primary gene-smoking interaction analyses. 287 
Investigation of the APOE locus: Although APOE has been recently established as a GWAS locus,7 288 
previous studies prior to GWAS have suggested that CHD risk is higher among carriers of the ε4 289 
allele at the APOE locus in smokers than in non-smokers.12-14 Because the ε2, ε3 and ε4 alleles at 290 
the APOE locus are not captured by the GWAS platform, we specifically conducted genotyping for 291 
rs429358 and rs7412 variants to capture the three epsilon (ε) alleles in 13,822 participants (including 292 
7,286 first-onset myocardial infarction cases) in the PROMIS study.15  293 
Gene-smoking interaction analyses at CHD and smoking loci: To assess gene-smoking interactions, 294 
analyses were conducted within each study, adjusted for age, sex and other study specific 295 
covariates (e.g., principal components), and variants were analyzed in association with CHD 296 
separately in “ever-smokers” and “never-smokers”. Results from the two groups were then used to 297 
test for interaction within each study. For the 50 variants, an interaction test statistic was calculated 298 
within each study using the following equation as adapted from Teslovich TM et.al.16  299 
(βn −  βe) 
√ܵܧ݊ଶ + ܵܧ݁ଶ 
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where βn and βe are the beta coefficients for the SNP in never-smokers and ever-smokers 300 
respectively, ܵܧ݊ and ܵܧ݁ are the standard errors for the log-ORs estimated for never-smokers and 301 
ever-smokers, respectively. Study specific interaction beta(s) and se(s) were calculated within each 302 
study and were pooled across studies using a fixed-effects meta-analysis. Interaction analyses were 303 
declared to be significant at a P-value of <1.0x10-3 (Bonferroni correction for 50 tests).  304 
Conditional analyses on chr.15q25.1: At chr.15q25.1, we observed two variants exhibiting gene-305 
smoking interactions for CHD. The proximity of these two signals raised the possibility that the 306 
observed interactions may represent a single interaction locus across the entire region. To 307 
investigate this possibility we undertook conditional analyses using an approximate conditional and 308 
joint analyses approach, also known as GCTA (Genome-wide Complex Trait Analysis), as described 309 
previously.17-22 Briefly, this method leverages summary-level statistics from a meta-analysis and uses 310 
LD corrections between SNPs estimated from a reference sample.  Such an approach has been 311 
shown to yield similar results to that obtained from conditional analyses conducted on individual 312 
participant data and has been successfully implemented in several other studies that have fine-313 
mapped loci for other complex traits.17-22 Using this approach, we first conducted separate 314 
conditional analyses at the chr.15q25.1 locus to identify main-effect variant(s) independently 315 
associated with CHD and smoking behavior, respectively. We used the meta-analyzed data for CHD 316 
main effects in the CARDIoGRAMplus4D consortium to identify SNPs independently associated with 317 
CHD risk and we used the genetic meta-analysis data from the Tobacco and Genetics Consortium 318 
(TGC) in 140,000 participants to identify variants independently associated with smoking behavior. 319 
We then estimated the effects of these independent variants on CHD risk stratified by smoking 320 
status and mutually adjusted the effects of these variants for each other.  321 
  322 
Analysis of eQTLs and regulatory features at the chr15q25.1 gene-smoking interaction locus 323 
eQTL analyses: We mined publicly available databases to identify genotype-related expression 324 
differences (eQTLs) in ADAMTS7 and the CHRNB4-A3-A5 gene cluster in order to understand the 325 
directionality of the association of expression of these genes with CHD and smoking behavior. 326 
Specifically, we investigated data available from the GTEx consortium,23 the HapMap consortium 327 
(restricted to European populations),` and the Multiple Tissue Human Expression Resource 328 
(MuTHER).24 We also analyzed expression data in 147 donor HAoEC lines.25 We used a nominal P-329 
value of 0.002 to account for multiple testing involved in the eQTL analyses. 330 
10 
 
Regulatory features of the chr. 15q25.1 region: Data from ENCODE26 were explored as described in 331 
eMethods. ChIP-seq experiments were performed on confluent HCASMC (Cell Applications 350-05a 332 
& Lonza CC-2583; cultured in SmGM-2 BulletKit media; Lonza) as described.27 TCF21 (Abcam 333 
ab49475), Jun (Santa Cruz Biotechnology sc-1694), JunD (Santa Cruz Biotechnology sc-74), and 334 
CEBP (Santa Cruz Biotechnology sc-150) transcription factor binding was interrogated and H3K27ac 335 
data were acquired using the same ChIP protocol with an anti-H3K27ac antibody (Abcam; ab4729). 336 
Reads were aligned to the human genome (GRCh37p13) using STAR.28   337 
 338 
Analyses of ADAMTS7 and CHRNB4-A3-A5 gene expression in vascular cells and tissues 339 
ADAMTS7 and CHRNB4-A3-A5 gene expression in vascular cells: ADAMTS7 and CHRNB4-A3-A5 340 
mRNA levels were measured in cultured human coronary artery smooth muscle cells (HCASMC; 341 
Lonza CC-2583, Lonza Walkersville, MD), human coronary artery endothelial cells (HCAEC, Lonza 342 
CC-2585), human aortic smooth muscle cells (HAoSMC, Lonza CC-2571), human aortic endothelial 343 
cells (HAoEC, Lonza CC-2535), human aortic adventitial fibroblasts (HAoAF, Lonza CC-7014), and 344 
human acute monocytic leukemia cell line (THP-1, ATCC TIB-202). Further details are provided in 345 
eMethods. 346 
ADAMTS7 and CHRNB4-A3-A5 gene expression in response to cigarette smoke extract: HCASMC 347 
were grown to confluence and cigarette smoke extract experiments performed at passage-7. 348 
Cigarette smoke extract was custom-prepared by Arista Laboratories (Richmond, VA). Briefly, the 349 
condensate was generated by smoking Marlboro Red King Size Hard Pack cigarettes on an 350 
analytical smoke machine under International Organization for Standardization smoking conditions. 351 
The smoke condensate was collected on 92 mm filter pads and extracted from each pad in DMSO 352 
by shaking to obtain a solution of ~20 mg/mL final concentration of the total particulate matter. 353 
Serum starved (24 hrs) HCASMC were treated with 0.5% or 1.0% cigarette smoke extract (v/v) for 4, 354 
12, and 24 hrs in serum reduced conditions (0.5% FBS in DMEM). Details on RNA preparation and 355 
q-PCR are provided in eMethods. 356 
 357 
 358 
 359 
 360 
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RESULTS 361 
Description of the participating studies  362 
Of the 37 studies participating in the CARDIoGRAMplusC4D consortium, information on 363 
“ever-smoking” was available in 30 studies, yielding a total sample size of 60,919 CHD cases and 364 
80,243 controls. All studies recruited participants of European ancestry, except PROMIS (South 365 
Asian),15 LOLIPOP (South Asian)29 and FGENTCARD (Lebanese).30 Number of CHD cases and 366 
controls and percentages that were “ever-smokers” are provided in eTable 1. As expected, in all the 367 
participating studies, association of “ever-smoking” status with CHD risk was directionally consistent 368 
with an increased risk of CHD (eFigure 2).  369 
New variants associated with CHD at established loci 370 
eFigure 3 and eTable 2 present effect estimates for the association with CHD for (i) the 371 
most significant variant that we identified at known CHD loci in the current CARDIoGRAMplusC4D 372 
consortium analysis as well as for (ii) the top SNP previously reported at each of these established 373 
CHD loci. Of the 45 established CHD loci, we identified 32 for which we discovered a more 374 
statistically significant SNP in association with CHD risk in our dataset than the prior reported top 375 
variant. All of these 32 SNPs were in moderate to high LD (r2 >0.6) with the previously published 376 
variants.7-9 In our primary gene-smoking interaction analyses, at each of the CHD loci, we, therefore, 377 
used the SNP with the most significant CHD association (eFigure 3 and eTable 2). Because the 378 
smoking behavior phenotype (captured as cigarettes per day [CPD]) was not available in all 379 
CARDIoGRAMplusC4D studies, we used the top variant previously reported for CPD10 at each locus 380 
(eFigure 4). 381 
Analyses of the APOE locus.  382 
The effect of rs6857, the lead CHD variant at the APOE locus, was similar in “ever-383 
smokers” compared to “never-smokers” (eTable 3).  Specifically, the CHD OR for the T allele at 384 
rs6857 was found to be 1.10 (P-value 7.93x10-4) in “never-smokers” (12,159 CHD cases and 22,932 385 
controls) which was quantitatively similar to the CHD OR of 1.09 (P-value: 8.68x10-5) observed in 386 
“ever-smokers” (23,753 CHD cases and 24,019 controls) (interaction P-value: 0.76) (eFigure 5a). 387 
Investigation in the PROMIS study of the APOE epsilon genotypes yielded consistent findings; the 388 
OR for CHD among ε4 carriers in “never-smokers” was 1.13 compared to the CHD OR of 1.07 389 
observed in “ever-smokers” (interaction P-value: 0.82) (eFigure 5a).  390 
 391 
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 392 
Novel gene-smoking interaction effects on CHD at chromosome 15q25.1  393 
Of the 50 loci, we identified effect-modification by “ever-smoking” status on CHD risk for the 394 
lead variants at two distinct loci, rs7178051, in proximity of ADAMTS7 (an established CHD locus), 395 
and rs1051730, in proximity of CHRNB4-A3-A5 (an established smoking behavior locus) (eTable 3). 396 
Although associated with different traits and located in distinct LD blocks, these two variants reside 397 
~224 KBs apart on chr.15q25.1 and are in weak linkage disequilibrium (LD) (r2 = 0.22), raising the 398 
question of whether these two chr.15q25.1 gene-smoking interactions on CHD are independent of 399 
each other.   400 
At the ADAMTS7 CHD locus, the T allele at the rs7178051 variant was found to be more 401 
strongly and inversely associated with CHD risk in never-smokers (OR: 0.88; P-value: 7.02x10-16) 402 
compared to a much weaker effect in ever-smokers (OR: 0.95; P-value: 8.64x10-4) (P-value of 403 
interaction: 8.57x10-5) (Table 1). Thus, the protective impact of the rs7178051 T allele observed in 404 
never-smokers was halved in people who smoked (Figure-1). This difference is not related to power 405 
differences within strata because for this variant, there were less data available in the never-smoking 406 
group (21,232 CHD cases and 38,713 controls) compared to the ever-smoking group (39,585 CHD 407 
cases and 40,749 controls). There was no substantial evidence of heterogeneity for the interaction 408 
beta across the participating studies (Heterogeneity chi-squared = 36.23 (d.f. = 25); P-value for the 409 
χ2 test of heterogeneity = 0.06; I2 = 31.0%; tau-squared (τ2 = 0). We further conducted sensitivity 410 
analyses using a random effect model; the results remained unchanged and the interaction beta 411 
remained signficiant (eFigure 5b). Although the frequency of rs7178051 was 39% in Europeans 412 
compared to 28% in South Asians, further analyses stratified by ancestry (i.e., European versus non-413 
Europeans) showed similar results (eFigure 5c). Other variants discovered through prior CHD 414 
GWAS at the ADAMTS7 locus (e.g., rs7173743, rs4380028, rs3825807) were in moderate to high 415 
LD (r2 >0.50) with rs7178051 and were also found to display a similar pattern of gene-smoking 416 
interaction effects (Table 1).  417 
At the CHRNB4-A3-A5 smoking locus, the A allele at the rs1051730 variant had an inverse 418 
trend (not significant after adjustment) of association with CHD in never-smokers (OR: 0.96; P-value: 419 
1.56x10-2) and a positive trend (not significant after adjustment) in ever-smokers (OR: 1.03; P-value: 420 
1.53x10-2) (P-value of interaction: 2.37x10-4) (Table 1 and eTable 3). For this variant, data on 421 
20,559 CHD cases and 38,198 controls were available in the never-smoking group whereas 38,923 422 
CHD cases and 40,371 controls were available in the ever-smoking group. Similar gene-smoking 423 
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interaction patterns were observed for other variants (e.g., rs2036527, rs8034191) that have been 424 
previously reported for CPD behavior at the CHRNB4-A3-A5 gene cluster (Table 1). 425 
Further interrogation of the chr15q21.1 region encompassing rs7178051 and rs1051730 426 
across three distinct LD blocks (Figure 1) revealed multiple additional variants for which we 427 
observed gene-smoking interactions in CHD (Table 1 and Figure 1). Indeed, several SNPs (e.g., 428 
rs7178051, rs10083696, rs7176187, rs6495335, rs4887077) had genome-wide significant 429 
associations with CHD in “never-smokers” but had weaker and less significant associations with 430 
CHD in “ever-smokers” (Figure 1). Alleles clustered specifically around ADAMTS7 rather than at the 431 
CHRNB4-A3-A5 genes appear to be protective of CHD in “never-smokers” but have attenuated 432 
protective effects in “ever-smokers” (Figure 2).  433 
Conditional analyses  434 
To investigate the possibility that the two chr.15q25.1 gene-smoking interactions might 435 
represent a single interaction locus across the entire region we undertook an approximate 436 
conditional and joint analyses17-22 using summary data derived from CARDIoGRAMplus4D for CHD 437 
and from the TGC for smoking behavior. In-addition to rs7178051, we identified one other variant, 438 
rs11072794 in low LD with rs7178051 (r2=0.20) that was associated independently with CHD 439 
(Figure 3a; red triangles) (Figure 3b & eFigure 6b; red triangles). We also confirmed two variants 440 
(rs1051730 and rs684513) located in two different LD blocks that were independently associated 441 
with smoking behavior in the TGC data10 (Figure 3d & eFigure 6b; grey circles).  442 
In analyses of the CHD variants, both rs7178051 and rs11072794 remained strongly 443 
associated with CHD after adjusting for the top CPD variants (rs1051730 and rs684513) (Figure 3d, 444 
red triangles) whereas their weak association with CPD was lost after adjusting for the top CPD 445 
variants (Figure 3d; grey circles); e.g., the P-value for rs7178051 association with CPD was 1x10-5 446 
in unadjusted analyses but attenuated to 0.55 after adjusting for rs1051730 and rs684513. In 447 
analyses of the CPD variants, both rs1051730 and rs684513 remained strongly associated with CPD 448 
after adjusting for the top CHD variants (rs7178051 and rs11072794) (Figure 3b, grey circles) 449 
whereas their weak association with CHD was lost after adjusting for the top CHD variants (Figure 450 
3b, red triangles). As expected, conditional analyses that included all four of these variants resulted 451 
in a null association of the region with both CHD and CPD (eFigure 6b).  To underscore the validity 452 
of the conditional approach using summary data, we used individual participant data from an 453 
expanded PROMIS sample involving 9,025 MI cases and 8,506 controls. We found that the OR 454 
conferred by allelic variation at rs7178051 remained associated with MI risk independent of the two 455 
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CPD variants (rs1051730 and rs684513) and rs11072794 (the second CHD SNP) (eFigure 6c). 456 
Conversely, the apparent effect of allelic variation at rs1051730 (the top CPD variant) on CHD risk 457 
was lost when we adjusted for the other three variants, rs7178051, rs11072794 and rs684513 458 
(eFigure 6c). 459 
Next, using summary level data we examined the association of each of these four variants 460 
with CHD risk separately in “ever-smokers” and “never-smokers” while mutually adjusting for the 461 
other three variants (Figure 4 & eFigure 7). In these analyses, only allelic variation at rs7178051 462 
was found to have independent genome-wide significant effects on CHD in never-smokers. 463 
rs7178051 was also the only one of these four variants with significant differences in the effect 464 
estimate for gene-CHD associations between the two smoking groups (P-value for the χ2 test of 465 
heterogeneity: 5.4x10-5) after adjusting for the effects of other variants (rs11072794, rs1051730 and 466 
rs684513).  These conditional analyses suggest that (a) variants located near the ADAMTS7 gene 467 
but not CHRNB4-A3-A5 genes have independent effects on CHD, (b) a single independent gene-468 
smoking interaction signal for CHD exists on chr.15q.25.1 which is localized at the ADAMTS7 CHD 469 
locus (marked by rs7178051) and (c) an apparent interaction signal observed at the nearby 470 
CHRNB4-A3-A5 CPD locus (marked by rs1051730) is not independent of the ADAMTS7 471 
(rs7178051) interaction signal.  472 
To assess the robustness of conditional analyses methodology that uses summary level data 473 
(i.e., GCTA)17-22, we conducted sensitivity analyses in the PROMIS dataset (9,025 MI cases and 474 
8,506 controls). We assessed the association of rs7178051 (top CHD SNP) and rs1051730 (top 475 
CPD SNP) after mutually adjusting for each other by conducting (i) standard logistic regression using 476 
individual participant data and (ii) summary level data in PROMIS using the GCTA method (eTable 477 
4). The top CHD SNP was found associated with CHD risk in PROMIS independent of the top CPD 478 
variant using both the methods, in-contrast the effect on CHD of the top CPD SNP attenuated 479 
sharply when adjusted for the top CHD SNP – the effect estimates obtained using the two methods 480 
were very similar (eTable 4).  481 
Finally, to further demonstrate that the gene-smoking interaction effect in CHD at rs7178051 is 482 
independent of the CHRNB4-A3-A5 CPD locus, we conducted sensitivity analyses in the PROMIS 483 
study by restricting our gene-environment interaction analysis to subjects who do not carry the minor 484 
alleles of rs1051730 and rs684513 (the two SNPs associated with CPD) at the CHRNB4-A3-A5 485 
locus. The T allele at the rs7178051 variant was associated with CHD only in never-smokers (OR: 486 
0.88; P-value: 0.01) compared to a weaker and non-significant association in ever-smokers (OR: 487 
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0.94; P-value: 0.21) (eTable 5). The effect estimates obtained in each of the categories defined by 488 
smoking status in PROMIS were similar to the effect estimates obtained in our overall meta-analyses 489 
that utilized data in all participants (eTable 5).  490 
 491 
Analysis of eQTLs and regulatory features at the chr15q25.1 gene-smoking interaction locus. 
517 
extract  518 
492 
We mined publicly available eQTL data from the HapMap consortium,11 GTEx consortium23 493 
and the MuTHER consortium24 as well as data from 147 HAoEC lines25 to examine the association 494 
between mRNA expression of ADAMTS7 and CHRN genes with CHD, CPD and gene-smoking 495 
interaction SNPs at the chr15q25.1 locus. SNP-mRNA associations with p-values <0.002 (correction 496 
for 20 tests) are presented (Figure 5). The top two CHD variants (rs7178051, rs11072794) are 497 
associated with reduced ADAMTS7 expression (e.g., rs11072794 p=6.01x10-21 in MuTHER LCL, 498 
n=850; and rs7178051 p=0.0029 in HAoEC, n=147) but have no association with expression of 499 
CHRN genes in any cell or tissue examined. In contrast, the top two CPD variants (rs1051730 and 500 
rs684513) were associated with CHRN gene expression (e.g., rs1051730 p=6.9x10-7 for CHRNA5 in 501 
GTEx skeletal muscle and nerve tissue) but have no association with ADAMTS7 in these cells or 502 
tissues. These findings complement conditional analyses suggesting that gene-CHD and gene-503 
smoking interaction effects on CHD are likely mediated by ADAMTS7 whereas the smoking behavior 504 
effect appears to be mediated through the CHRNA3-5 gene cluster.  505 
In analysis of data from the ENCODE project26 and for human aortic tissue in NIH 506 
Roadmap Epigenomics project, ADAMTS7 was associated with RNAseq reads and an active 507 
transcription mark, H3K36me3, whereas CHRN genes had low/absent RNAseq reads and were 508 
positive for repressive marks, H3K27me3 and H3K9me3 (eFigure 8). In HCASMC ChIPseq data, 509 
rs7178051 the top CHD and gene-smoking CHD interacting SNP, is located in a region with active 510 
regulatory marks H3K4me1 and H3K4me3 as well as transcription factor binding site for TCF21, an 511 
important HCASMC transcription factor also associated with CAD. This ChIPseq pattern was 512 
observed also in human aortic tissue (Figure 6).  These regulatory data suggest active transcription 513 
of ADAMTS7, but not CHRN genes, in vascular cells and aortic tissue and reveal that rs7178051, 514 
the lead gene-smoking CHD interaction SNP, overlaps active transcription marks and transcription 515 
factor binding regions in HCASMC.    516 
ADAMTS7 and CHRNB4-A3-A5 expression in vascular cells and their response to cigarette smoke 
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In order to explore which genes at the chr15q25.1 locus are expressed in CHD-relevant 519 
vascular cells, we performed q-PCR of ADAMTS7 and the CHRNB4-A3-A5 genes in primary human 520 
vascular cells and in the THP1 human monocyte cell line (eFigure 9 & Figure 5). Whilst ADAMTS7 521 
mRNA was expressed abundantly in all vascular cell types, mRNA was below detection or 522 
expressed at a very low level for each of the genes in the CHRNB4-A3-A5 cluster in any of these cell 523 
types (eFigure 9). Next, we explored the effect of cigarette smoke extract on gene expression in 524 
HCASMC, a cell type of particular relevance to vascular responses to cigarette smoke products31, 32 525 
as well as to ADAMTS7 vascular functions in atherosclerosis and CHD.33 In primary HCASMC, 526 
cigarette smoke extract exposure increased ADAMTS7 mRNA levels by over 2-fold (Figure 5) but 527 
did not affect expression of the CHRN genes (not shown).  Thus, in contrast to CHRN genes, 528 
ADAMTS7 is both expressed and modulated by cigarette smoke extract in CHD-relevant vascular 529 
cells providing biological support for ADAMTS7, but not CHRN genes, in the gene-smoking 530 
interaction at chr15q25.1.     531 
 532 
 533 
 534 
 535 
 536 
 537 
 538 
 539 
 540 
 541 
 542 
 543 
 544 
 545 
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DISCUSSION 546 
We conducted a gene-environment interaction study at fifty loci associated with either CHD 547 
or smoking behavior and found evidence of effect-modification of genotype-related CHD risk by 548 
smoking-behavior at the chr.15q21.1 CHD locus. Specifically, we observed highly significant 549 
attenuation of the cardio-protective effects conferred by alleles at this locus in people who smoked 550 
cigarettes.  Conditional analyses identified an LD block located at the ADAMTS7 gene that 551 
accounted for both the main effect on CHD as well as the gene-smoking interactions in CHD. Data 552 
from expression and cell studies support our genetic analysis, suggesting that the underlying 553 
mechanism relates to genotype differences in the effect of smoking on expression of ADAMTS7 in 554 
vascular tissue.  555 
Our findings have novel mechanistic and clinical implications. These human genomic data 556 
provide new insights into the mechanism of CHD in cigarette smokers. Identification of gene-557 
smoking interaction at the chr15q21.1 locus suggests a specific role in smoking-related CHD for 558 
ADAMTS7 and its substrates, vascular matrix and vascular smooth muscle cell biology more 559 
broadly. Such insights can help to prioritize translational strategies for smoking-related CHD and 560 
present opportunities to study lifestyle interventions and pharmacological strategies to lower CHD in 561 
individuals who smoke cigarettes. Thus, inhibition of ADAMTS7 represents a novel potential 562 
therapeutic strategy for CHD that may have particular benefits in individuals who smoke cigarettes. 563 
All smokers should receive counseling for smoking cessation yet such broad public health strategies 564 
have failed to reach or impact smoking behavior in a large portion of nicotine-addicted individuals. 565 
Our data provides a human genomic context for consideration of targeting specific genetically at-risk 566 
individuals via intensified preventive strategies and development of novel pharmacological 567 
treatments.  568 
Our study also represents a realistic strategy for performing gene-environment interaction 569 
studies using contemporary genetic data. We illustrate that identifying joint effects of genetic and 570 
lifestyle factors in CHD requires very large sample sizes, yet such analyses are biologically 571 
informative when studies are adequately powered. In this context, an important observation in our 572 
large sample is the lack of effect modification by smoking behavior on CHD at the APOE locus, a 573 
previously reported smoking interaction locus.12-14 This finding is consistent with a recent meta-574 
analysis that found no evidence of effect modification by smoking for APOE genotypes and CHD 575 
risk.34 These studies raise concerns that most prior gene-environment interactions studies in CHD 576 
have been prone to the same biases (i.e., limited statistical power and false positive associations) as 577 
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candidate gene studies investigating main effects in the pre-GWAS era. The present study differs 578 
from previous studies by being much larger and, importantly, it includes genomic and functional 579 
follow-up data supporting the plausibility of the observed gene-environment interaction. 580 
ADAMTS7 (or the A disintegrin and metalloproteinase with thrombospondin motifs-7) is a 581 
member of the ADAMTS family of secreted zinc metalloproteases.35, 36 We previously discovered 582 
and replicated genetic variation at the ADAMTS7 locus in association with coronary atherosclerosis 583 
and MI.7-9 Both in vivo and in vitro studies suggest that ADAMTS7 modulates VSMC phenotype 584 
switching and migration and that this may be mediated via cartilage oligomeric matrix protein 585 
(COMP) or thrombospondin-1 (TSP-1),32,33 i.e. putative ADAMTS7 substrates expressed in vascular 586 
tissue. Genetic variation at ADAMTS7, however, has no relationship with traditional risk factors or 587 
mechanistic biomarkers; hence the directional impact of ADAMTS7 expression on CHD risk and the 588 
underlying biological mechanisms have been unclear.32 589 
Our gene-smoking interaction analyses provide novel insights into the directional impact of 590 
the ADAMTS7 locus on CHD, the underlying mechanisms of CHD in smokers, and how such 591 
findings ultimately might translate towards achieving health benefits in society. Our human eQTL 592 
interrogations reveal that common alleles that relate to lower CHD risk at the ADAMTS7 locus are 593 
also associated with reduced ADAMTS7 expression, implying an atherogenic role of the gene. This 594 
is supported by our recent in vivo experimental studies; Adamts7 deficiency protected against diet-595 
induced atherosclerosis in both the Ldlr-/- and ApoE-/- mouse models, reduced neointima formation 596 
following arterial injury, and decreased VSMC migration in vitro.33 In our smoking-stratified analyses, 597 
we observed CHD protective effect which was attenuated in smokers. Thus, smoking exposure may 598 
overcome the genetic effect of protective alleles that act by reducing ADAMTS7 expression. Such a 599 
possibility is supported by our HCASMC data that reveals increased ADAMTS7 expression in 600 
HCASMC exposed to cigarette smoke extract. These human genome-smoking studies are the first to 601 
implicate a specific locus as causal in mediating increased risk of CHD in smokers. Additional 602 
translational studies are needed to establish the precise mechanisms of atheroprotection for alleles 603 
at the ADAMTS7 locus, how cigarette smoking impacts these genetic effects, and whether deletion 604 
or inhibition of ADAMTS7 in vivo attenuates the specific acceleration of atherosclerosis conferred by 605 
cigarette smoking.  606 
Strengths and limitations of our study merit consideration. This is a large study that 607 
conducted gene-smoking interaction analyses in CHD by using GWAS data. We observed 608 
substantial heterogeneity across study samples in our initial quality control analyses of “ever-609 
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smoking” status with CHD risk. This is similar, however, to the heterogeneity reported in a recent 610 
meta-analysis that pooled risk ratios from all the past prospective studies with information on 611 
association of “ever-smoking” with incident CHD events.5 We recognize that other smoking related 612 
phenotypes are important e.g., “current smoking” may have a more pronounced role than “ever-613 
smoking” in plaque rupture and thrombosis in patients with MI. “Current smoking” status and MI 614 
phenotypes were available only in a subset of our studies limiting statistical power. Given the use of 615 
multiple studies and meta-analyses of data, we used only one analytical approach to investigate 616 
gene-smoking interactions. This approach, however, was feasible and powerful in this large-scale 617 
consortium setting. While we used a fixed effects approach in our meta-analyses, a random effects 618 
meta-analysis yielded qualitatively similar results (data not shown). The lack or replication is partially 619 
offset by a large sample size, consistency across study cohorts and racial groups and supplemental 620 
genomic and experimental evidence supporting biological plausibility. This approach is also 621 
consistent with recent recommendations37 which favor use of a powerful discovery experiment using 622 
all data rather than reducing power by splitting available dataset for discovery and validation. While 623 
our in vitro studies support a role for ADAMTS7 in the gene-smoking interaction, it will be important 624 
to confirm that Adamts7 deficiency protect against cigarette-smoke acceleration of atherosclerosis in 625 
rodent models.  626 
Our interaction analyses, conditional analyses, eQTL interrogations and cell studies 627 
suggest that ADAMTS7, but not the CHRNB4-A3-A5 gene cluster, is likely causal at 15q21.1 for 628 
gene-smoking interaction effects in CHD. Yet, analyses are not definitive. Although top interacting 629 
SNPs and CHD SNPs (e.g., rs7178051) were associated with ADAMTS7, but not CHRNB4-A3-A5, 630 
expression in LCLs, large-scale eQTL data and allele specific expression data (e.g., via RNA 631 
sequencing) are not available for vascular tissues limiting causal inference. In our small HCAEC 632 
datasets, we did however find that alleles at rs7178051 associate with ADAMTS7 expression but not 633 
with any CHRNB4-A3-A5 genes suggesting, at least in one vascular cell type, that the gene-smoking 634 
interaction is mediated via ADAMTS7.  635 
 636 
 637 
 638 
 639 
 640 
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Conclusions 641 
We provide novel evidence for allelic variation exhibiting gene-smoking interaction in CHD 642 
at the chr.15q21.1 locus. The protective effect conferred by variation at this locus in never-smokers 643 
is markedly attenuated in people who are ever-smokers. Stepwise conditional analyses, gene 644 
expression data in vascular cells, eQTL interrogation, and cigarette smoke extract exposure in 645 
HCASMC suggest that ADAMTS7 accounts for both the gene-smoking interaction in CHD and the 646 
CHD main effect on chr.15q21.1. Our findings reveal interactions of genetic variants and key lifestyle 647 
determinants in the etiology of CHD, provide new insights into the potential mechanisms of CHD in 648 
cigarette smokers, and facilitate precision medicine advances in cigarette-smoking related CHD. Our 649 
work motivates future large-scale studies investigating joint effects of genes and environment in 650 
CHD using existing complex-disease consortia datasets and genome-wide discovery approaches. 651 
This will provide opportunities to detect additional and novel loci displaying gene-environment 652 
interactions revealing genetic contexts for targeting intensive lifestyle interventions and novel 653 
therapeutics. 654 
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 1073 
 1074 
Figure Legends 1075 
 1076 
Figure 1. (a) Regional association analyses at the chromosome 15q25.1 locus in association with 1077 
CHD risk stratified by smoking status. Association P-values for genetic variants with CHD risk in 1078 
“never-smokers” (green squares) and “ever-smokers” (red triangles). (b) Longitudinal bars represent 1079 
gene-smoking CHD interaction P-values at the chromosome 15q25.1 locus; bars in blue are P-1080 
values for variants listed in Table-1 and each variant has been assigned a unique identification 1081 
number based on its physical location; (c) LD-blocks at the 15q25.1 locus visualized through 1082 
HAPLOVIEW using LD estimates in the HapMAP-2 CEU reference population.  1083 
 1084 
Figure 2. Several variants at chromosome 15q21.1 have stronger effects on CHD risk in “never-1085 
smokers” compared to “ever-smokers”. Variants with the strongest interaction P-value are displayed. 1086 
 1087 
Figure 3. Step-wise conditional analysis of genetic variation at the chromosome 15q21.1 locus with 1088 
CHD (red triangles) and smoking behavior (cigarettes per day, CPD; grey circles). At the 1089 
chromosome 15q21.1 locus, analyses adjusted for rs7178051 and rs11072794 completely 1090 
attenuated the gene-CHD associations whereas gene-smoking remained unchanged. Analyses 1091 
adjusted for rs1051730 and rs684513 completely attenuated the gene-smoking associations 1092 
whereas gene-CHD effect remained unchanged. 1093 
Figure 4. Analyses mutually adjusted for rs7178051, rs11072794, rs1051730 and rs684513 at 1094 
15q21.1 on CHD and smoking behavior; gene-CHD interaction analyses were only found significant 1095 
for rs7178051. 1096 
Figure 5.  Genome browser view of regulatory features at rs7178051 on Chr15q21.1.  ChIP-seq 1097 
experiments were performed on confluent HCASMC for TCF21, Jun, JunD, CEBP and H3K4me1, 1098 
H3K27me3, H3K27ac. DNAaseI hypersensitivity data for human AoSMC were acquired from the 1099 
ENCODE project.  Human aortic tissue H3K4me1, H3K9me3, H3K27me3, and H3K36me3 ChIP-seq 1100 
data were acquired from the NIH Roadmap Epigenomics Project.  HCASMC = human coronary 1101 
artery smooth muscle cells; AoSMC = human aortic smooth muscle cells.   1102 
Figure 6.  (a) ADAMTS7 and CHRNB4-A3-A5 mRNA levels were measured in HCASMC. Cells were 1103 
cultured to confluence, total RNA was extracted and cDNA generated. q-PCR was performed for 1104 
ACTB, GAPDH, TBP, ADAMTS7, CHRNB4, CHRNA3, CHRNA5 (95°C 15s, 60°C 1min). Delta Cts 1105 
32 
 
were calculated as follows:  (CtACTB + CtGAPDH + CtTBP)/3 – CtTARGET GENE). Fold changes are derived 1106 
from delta delta Cts based on formula FC = 2-dCt. (b) Confluent HCASMC were exposed to cigarette 1107 
smoke extract. Serum starved (x24 hrs.) confluent HCASMC were treated with 0.5% or 1.0% 1108 
cigarette smoke extract  (v/v) for 4, 12, and 24 hrs. in serum reduced conditions (0.5% FBS in 1109 
DMEM). Total RNA was extracted, cDNA generated preparation and q-PCR performed for 1110 
ADAMTS7 by Taqman and normalized to GAPDH. The Average Ct for ADAMTS7 at baseline was 1111 
28.25. Results were presented as means ± SEM, and data were analyzed using Student’s t-Test. (c) 1112 
expression and eQTL Data from the GTEx consortium, the HapMap consortium (restricted to 1113 
European populations), the Multiple Tissue Human Expression Resource (MuTHER) and in 147 1114 
donor HAoEC lines. Association of the independent lead variants identified in our conditional 1115 
analyses with expression of ADAMTS7 and genes in the CHRNB4-A3-A5 cluster. A P-value 1116 
threshold of 0.002 was set to account for multiple testing involved in the eQTL analyses. 1117 
 1118 
 1119 
 1120 
 1121 
Table-1. Novel genotype-smoking interaction findings in coronary heart disease at the chromosome 15q25.1 locus  
      Never Smokers  Ever Smokers   
Variant Association allele LD with 
rs7178051* 
LD with 
rs1051730^ 
 N 
cases 
N 
controls 
N 
Total 
Beta (SE) P-value  N 
cases 
N 
controls 
N 
Total 
Beta (SE) P-value  P-value 
interaction 
*rs71780514 CHD (NPR) T/C - 0.22  21232 38713 59945 -0.13 (0.01) 1.30E-16  39585 40749 80334 -0.05 (.01) 2.49E-04  8.57E-05 
^rs105173016 SB (known) A/G 0.22 -  20559 38198 58757 -0.04 (0.02) 0.02  38923 40371 79294 0.03 (0.01) 0.02  2.37E-04 
Other variants on chr.15q25.1 with significant gene-smoking interactions on CHD 
rs71737431 CHD (Known) C/T 0.61 0.18  21050 37955 59005 -0.11 (0.01) 2.73E-13  39044 39559 78603 -0.04 (0.01) 8.60E-04  9.29E-05 
rs100836962 CHD (Novel) A/G 1.0 0.22  19721 36206 55927 -0.11 (0.02) 1.60E-12  38807 40018 78825 -0.05 (0.01) 2.72E-04  5.15E-05 
rs71761873 CHD (Novel) T/C 1.0 0.24  21232 38713 59945 -0.12 (0.01) 7.02E-16  39585 40749 80334 -0.04 (0.01) 8.64E-04  6.93E-05 
rs64953355 CHD (Novel) G/T 1.0 0.22  20144 37217 57361 -0.13 (0.02) 2.39E-15  36448 38203 74651 -0.04 (0.01) 1.69E-03  9.51E-04 
rs43800286 CHD (Known) T/C 1 0.22  21232 38713 59945 -0.12 (0.01) 2.20E-15  39585 40749 80334 -0.04 (.01) 1.03E-03  5.44E-04 
rs38258077 CHD (Known) G/A 0.52 0.43  17137 28633 45771 -0.09 (0.02) 2.82E-08  30071 29014 59086 -0.03 (0.01) 0.04  2.6E-03 
rs38135658 CHD (NPR) T/G 0.43 0.56  19466 35830 55296 -0.08 (0.02) 5.08E-07  36642 37759 74401 -0.01 (0.01) 0.42  3.05E-04 
rs116384909 CHD (NPR) T/C 0.44 0.51  20465 37897 58362 -0.08 (0.01) 6.90E-08  38533 39690 78223 -0.01 (0.01) 0.28  2.25E-04 
rs1107279111 CHD (NPR) A/C 0.44 0.51  19289 35944 55233 -0.08 (0.02) 2.83E-07  35245 36635 71880 -.005 (0.01) 0.68  1.06E-04 
rs92269212 CHD (NPR) A/C 0.44 0.50  20559 38198 58757 -0.08 (0.01) 2.81E-07  38923 40371 79294 -0.01 (0.01) 0.29  2.75E-04 
rs1163837213 CHD (NPR) T/C 0.44 0.50  21232 38713 59945 -0.08 (0.01) 6.92E-08  39585 40749 80334 -0.01 (0.01) 0.23  3.16E-04 
rs488707714 CHD (NPR)  T/C 0.44 0.50  21232 38713 59945 -0.08 (0.01) 4.71E-08  39585 40749 80334 -0.02 (0.01) 0.20  3.92E-05 
rs1289913515 CHD (NPR) G/A 0.39 0.56  20377 37440 57817 -0.07 (0.02) 3.97E-06  38382 39181 77563 -0.01 (0.01) 0.58  4.54E-04 
rs68451318 SB (Known) C/G 0.01 0.10  12517 21054 33572 -0.01 (0.02) 0.67  24641 24487 49129 0.03 (0.02) 0.18  0.08 
rs203652719 SB (Known) A/G 0.17 0.90  20559 38198 58757 -0.04 (0.02) 0.02  38923 40371 79294 0.03 (0.01) 0.02  2.14E-04 
rs1051920320 CHD (NPR) G/A 0.19 0.93  21232 38713 59945 -0.04 (0.01) 5.93E-03  39585 40749 80334 0.03 (0.01) 0.03  1.27E-04 
rs803419121 SB (Known) C/T 0.19 1.0  19251 32131 51382 -0.05 (0.02) 2.62E-03  34925 34047 68972 0.02 (0.01) 0.06  3.91E-05 
CHD = coronary heart disease;  SB = smoking behavior; NPR: Not a previously reported variant with disease risk 
*lead variant in association with CHD in our dataset; ^ lead variant in association with SB 
1-21each number refers to the physical location of the variant in figure-
Figure-1. Analyses of the chromosome 15q25.1 locus association with CHD stratified by 
smoking status and gene-smoking CHD interaction analyses  
 
1-rs7173743; 2-rs10083696; 3-rs7176187; 4-rs7178051; 5-rs6495335; 6-rs4380028; 7-rs3825807; 8-rs3813565;  9-rs11638490;  
10-rs11072794; 11-rs11072791; 12-rs922692; 13-rs11638372; 14-rs4887077; 15-rs12899135; 16-rs17487514; 17-rs1051730;  
18-rs637137; 19-rs2036527; 20-rs10519203; 21-rs8034191. LD 1-3 indicate three separate linkage disequilibrium blocks in 
European ancestry at the chromosome 15q25.1 locus.   
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Figure-2. Multiple variants at chromosome 15q21.1 have stronger effects on CHD risk in 
“never-smokers” compared to “ever-smokers” 
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rs7178051 is the lead variant identified in association with CHD in our study population; whereas rs1051730 is the 
lead variant previously identified in association with smoking behavior .
Variants are ordered based on their base pair position in Figure-1. 
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Figure 3. Conditional analysis of genetic variation at the chromosome 15q21.1 locus with coronary heart disease (CHD; red 
triangles) and smoking behavior (cigarettes per day, CPD; grey circles) 
 
 
Figure 4. Mutually adjusted effects of 15q21.1 lead variants on coronary heart disease and smoking behavior  
 
 
Gene-CHD and gene-smoking analyses for rs7178051 were adjusted for rs11072794, rs1051730 and rs684513; 
Gene-CHD and gene-smoking analyses for rs11072794 were adjusted for rs7178051, rs1051730 and rs684513; 
Gene-CHD and gene-smoking analyses for rs1051730 were adjusted for rs7178051, rs11072794 and rs684513; 
Gene-CHD and gene-smoking analyses for rs684513 were adjusted for rs7178051, rs11072794 and rs1051730. 
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Figure-5. (a) Expression of ADAMTS7 and CHRNB4-A3-A5 mRNAs and (b) cigarette smoke extract (CSE) induction of ADAMTS7 
mRNA in primary human coronary artery smooth muscle cells  
 
Figure-5c. Association of lead CHD and smoking behavior variants with candidate gene expression in available cells and tissues 
#Direction of association for the effect allele on CHD; NS: Not significant (P-value < 0.002; Bonferroni correction for 20 tests); HAEC: Human Aortic Endothelial Cells; LCL: 
lymphoblastoid cell lines; 1 Association with CHRNA5 expression; 
 
   LCL in the MuTHER 
consortium (n=850) 
 HAEC (n=147)  HapMap CEU LCL 
(n=109) 
 GTEx Skeletal muscle 
(n= 142) 
 GTEx Nerve Tibial 
(n=101) 
Variant Type CHD 
direct.# 
ADAMTS7 CHRNA3-5  ADAMTS7 CHRNA3-5  ADAMTS7 CHRNA3-5  ADAMTS7 CHRNA3-5  ADAMTS7 CHRNA3-5 
rs7178051 Top CHD 
signal 
- 4.1e-4 (-) NS  0.0029 (-) NS  NS NS  NS NS  NS NS 
rs11072794 Second CHD 
signal 
- 6.0E-21 (-) NS  NA NS  0.0013 (-) NS  NS NS  NS NS 
rs1051730 Top CPD 
signal 
- NS NS  NS NS  NS NS  NS 6.9E-7 (-)1  NS 6.9E-71 
rs684513 Second CPD 
signal 
- NS NS  NS NS  NS NS  NS 2.4E-7 (-)1  NS NS 
Figure-6. Genome browser view of regulatory features at rs7178051 on Chr15q21.1  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
